LENSAR, Inc.
HealthcareNASDAQ:LNSR · NASDAQ Capital Market
+$0.00 today
Vol 0.03M · Avg 0.12M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
131.7%
avg -8.8%
ROIC
-77.8%
avg -39.3%
ROA
-48.0%
avg -36.5%
Analysis
ROE is currently the strongest return metric at 131.7% versus its period average of -8.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Nicholas T. Curtis | President, Chief Executive Officer & Director | $1.04M | — | 70 | $1.12M | 9.28% |
Alan Connaughton | Chief Operating Officer | $694,196.00 | — | 54 | $389,173.00 | 3.22% |
Thomas R. Staab | Chief Financial Officer & Secretary | $687,754.00 | — | 58 | $56,083.00 | 0.46% |
Michael A. Rossi | Interim CFO & Principal Financial Officer | — | — | 52 | $0.00 | <0.01% |
Kendra W. Wong | Principal Accounting Officer | — | — | 46 | $56,481.00 | 0.47% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +5.0% | +20.1% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +5.0% over three years. Forward estimates point to Revenue at +20.1% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Anika Therapeutics, Inc.
NASDAQ:ANIK
$195.86M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Owlet, Inc.
NYSE:OWLT
$84.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Accuray Incorporated
ARAY
$40.60M
Who manages LNSR?
LENSAR, Inc. (LNSR) lists 5 active executives. The top listed executive is Michael A. Rossi, Interim CFO & Principal Financial Officer.
Are LNSR insiders buying or selling?
Recent insider activity shows net buying of $6.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.